Clinical Trial Detail

NCT ID NCT02794571
Title Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech, Inc.
Indications

Advanced Solid Tumor

Therapies

Atezolizumab + MTIG7192A

MTIG7192A

Age Groups: adult

No variant requirements are available.